COPIAGUE, N.Y., March 9 -- American Biogenetic Sciences,
Inc. (ABS) (Nasdaq: MABXA) has announced
the appointment of Glenna M. Crooks, Ph.D. to the
Company's Board of Directors. Dr. Crooks' distinguished
career in pharmaceutical operations and policy with
Merck & Co. as well as her governmental expertise
brings a wealth of relevant experience to the ABS
``Dr. Crooks brings a new dimension of experience
to our Board, at a critical and exciting juncture
for ABS,'' said John S. North, President and CEO.
``Having been responsible for business development
decisions as a major player in the global pharmaceutical
industry, Glenna's counsel will be invaluable as ABS
engages in negotiations with licensing and commercialization
Dr. Crooks' pharmaceutical industry experience culminated
with her appointment in 1994 as Vice President, Worldwide
Sales and Operations for the Merck and Company Vaccines
Division. In that capacity, she developed and managed
a global organization responsible for strategic, marketing
and tactical planning, business development and negotiations,
joint venture management and product sales and marketing
for all operations outside the U.S. In 1990, she was
the recipient of the Merck Management Award for her
development and implementation of the Merck Equal
Access to Medicines Plan. In 1989 she received the
highest award in public health, the Surgeon General's
Exemplary Service Medallion by Surgeon General C.
Prior to joining Merck, Dr. Crooks served from 1981
to 1985 as Deputy Assistant Secretary for Health during
the Reagan Administration. There, she was responsible
for policy formulation, strategic and budget planning,
legislation development, regulation and management
of federal government health policy staff.
Dr. Crooks is the Founder and President of Strategic
Health Policy International, Inc., a health care consulting
and planning firm that advises governments, businesses
and industry trade associations in the U.S. and overseas
on the development and application of business strategy.
She received an M.S. in Educational Psychology and
a Ph.D. in Interdisciplinary Studies from the University
of Indiana, and is currently authoring a book, entitled
``Broken Covenants: Healing Health Care Relationships.''
Expertise in Business Development
``Dr. Crooks is an ideal addition to the ABS team
and we are extremely pleased to welcome a Director
of her quality and accomplishment,'' said Alfred J.
Roach, Chairman of the Board.
``I look forward eagerly to working with the ABS
Board and management,'' said Dr. Crooks. ``ABS' diagnostic
tests and neuroscience compounds represent an enviable
portfolio of commercially viable products with features
and benefits matched to the needs of today's and tomorrow's
market. I am excited to be joining the company at
American Biogenetic Sciences, based in Copiague,
New York, researches and develops diagnostic tests
for cardiac conditions and infectious diseases, as
well as new treatments for neurological disorders
including epilepsy, migraine, mania, Parkinsons and
Alzheimer's disease. ABS also seeks out new technologies
and conducts research and development throughout its
Global Scientific Network, in the U.S., Europe, Israel,
Russia and China.
Statements in this release that are not strictly
historical are ``forward-looking'' statements within
the meaning of the Private Securities Litigation Reform
Act of 1995, and should be considered as subject to
various risks and uncertainties that could cause actual
results to differ materially from those anticipated.
For further details and a discussion of these risks
and uncertainties, see the Company's Securities and
Exchange Commission filings, including its annual
report or Form 10-K.